Bioequivalence Study of Individual Atazanavir and Cobicistat Compared With Atazanavir in Fixed-dose Combination With Cobicistat
Completed · Phase 1
Conditions studied: Human Immunodeficiency Virus Type 1 (HIV-1)
In brief
The purpose of the study is to compare the pharmacokinetics and bioequivalence of atazanavir in a fixed-dose combination with cobicistat with that of atazanavir coadministered with cobicistat as single agents.
Key facts
- Study ID
- NCT01837719
- Run by
- Bristol-Myers Squibb
- People needed
- 64
- Starts
- 2013-04-01
- Expected to finish
- 2013-06-01
- Last updated by the study team
- 2014-08-29
Who can join
Age: 18 and older, up to 49. Sex: any. Healthy volunteers: accepted.
Where it is running
- Ppd Development, Inc. — Austin, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.